Values as of: 2025-01-11
COMMON STOCK | Biotechnology |
Last Closing
USD 1.693Change
0.00 (0.00)%Market Cap
USD 0.48BVolume
0.01MAnalyst Target
USD 3.50Verdict
Verdict
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Company Website : https://www.puretechhealth.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 39.01B |
| UCBJF | UCB SA |
N/A |
USD 37.94B |
| UCBJY | UCB SA ADR |
N/A |
USD 37.34B |
| GNMSF | Genmab A/S |
N/A |
USD 13.64B |
| WXIBF | WuXi Biologics |
N/A |
USD 8.99B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 8.93B |
| IVBIY | IVBIY |
N/A |
USD 7.80B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.48B |
| ZLDPF | Zealand Pharma A/S |
N/A |
USD 7.14B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 6.89B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -15.35% | 16% | F | 9% | A- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -15.35% | 16% | F | 9% | A- | ||
| Trailing 12 Months | |||||||
| Capital Gain | -27.03% | 50% | F | 35% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -27.03% | 50% | F | 33% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -54.85% | 66% | D+ | 37% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -54.85% | 66% | D+ | 35% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -4.27% | 42% | F | 30% | F | ||
| Dividend Return | -4.27% | 42% | F | 27% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 36.11% | 83% | B | 65% | D | ||
| Risk Adjusted Return | -11.82% | 39% | F | 27% | F | ||
| Market Capitalization | 0.48B | 88% | B+ | 68% | D+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
